Business
Helix BioPharma's L-DOS47 to be Highlighted at Pharmaceutical Industry Conference
Helix BioPharma's L-DOS47 to be Highlighted at Pharmaceutical Industry Conference
About this update from Helix Biopharma Corp.
[{"type":"text","content":"\n\n\n\nOct. 14, 2009 (Canada NewsWire Group) -- AURORA, Ontario, Oct. 14 /CNW/ -- Dr. Tim Kelly, Vice President, Biopharmaceutical Development of KBI Biopharma, Durham N.C., will describe their work on L-DOS47 formulation development. Dr. Kelly's presentation, entitled \"Case Study: Novel Protein Therapeutics, Formulation Development for L-DOS47,\" will take place at 12:00 p.m., EDT on October 14. KBI Biopharma provides Helix formulation support and conducts analytical and stability studies on L-DOS47 cGMP materials.AURORA, Ontario, Oct. 14 /CNW/ -- For additional information on the IBC's Formulation Strategies for Protein Therapeutics conference visit http://www.ibclifesciences.com/formulation/overview.xml.About L-DOS47L-DOS47 combines Helix's proprietary DOS47 new drug candidate with a highly specific single domain antibody, to form a potential new targeted drug product for the treatment of adenocarcinoma of the lung, the most common form of lung cancer in the world today. L-DOS47 is thought to function by leveraging a natural process in the body called the urea cycle, to produce an anti-cancer effect. It is based upon a naturally occurring enzyme called urease that essentially reverses the urea cycle by breaking down urea into metabolites that include ammonia and hydroxyl ions. By doing so at the site of cancerous tissues in the body, L-DOS47 is believed to modify the microenvironmental conditions of lung cancer cells in a manner that leads to their death. Among these theorized effects, L-DOS47 is believed to stimulate an increase in the pH of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extra-cellular conditions that are known to be necessary for cancer cell survival. As well, the local production of ammonia at the site of cancerous tissues is thought to readily diffuse into the cancer cells to exert a potent cytotoxic effect by interfering with their critical metabolic functions.About Helix BioPharma Corp.Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha- 2b. Helix is listed on the TS...